Agios Pharmaceuticals, Inc. (AGIO) News

Agios Pharmaceuticals, Inc. (AGIO): $20.61

-0.54 (-2.55%)

POWR Rating

Component Grades













Add AGIO to Watchlist
Sign Up

Industry: Biotech


of 395

in industry

Filter AGIO News Items

AGIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGIO News Highlights

  • For AGIO, its 30 day story count is now at 23.
  • Over the past 23 days, the trend for AGIO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • DRUG, PK and PFE are the most mentioned tickers in articles about AGIO.

Latest AGIO News From Around the Web

Below are the latest news stories about Agios Pharmaceuticals Inc that investors may wish to consider to help them evaluate AGIO as an investment opportunity.

Agios Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Yahoo | February 24, 2022

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Yahoo | February 24, 2022

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First Patients Dosed in All Three Pivotal Trials of PYRUKYND® in Thalassemia and Sickle Cell Disease – – Cash, Cash Equivalents and Marketable Securities $1.3 Billion as of Dec. 31; Expects Strong Cash Position to Enable Execution of Robust Operating Plan to Cash-Flow Positivity – CAMBRIDGE, Mass., Feb. 24,

Yahoo | February 24, 2022

Agios Pharmaceuticals With FDA Approval Is A Buy

Agios Pharmaceuticals (AGIO) specializes in creating therapies for diseases related to cellular metabolism. Its first approved drug was Idhifa, which was approved for treating IDH mutation driven cancers, in 2017. That was followed by approval of Tibsovo for acute myeloid leukemia in 2018. In 2021 Agios sold its cancer therapy...

William Meyers on Seeking Alpha | February 23, 2022

Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Yahoo | February 23, 2022

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant wome...

Benzinga | February 20, 2022

Agios Pyrukynd for rare blood disorder gets US FDA approval

The U.S. Food and Drug Administration ((FDA)) approved Agios Pharmaceuticals'' (AGIO) Pyrukynd (mitapivat) to treat hemolytic anemia in adults with pyruvate kinase ((PK))…

Seeking Alpha | February 18, 2022

Agios stock gains as H.C. Wainwright raises target on FDA approval (NASDAQ:AGIO)

Agios Pharmaceuticals (AGIO) is trading ~2% higher in the pre-market on Friday as Wall Street reacts to the FDA approval for the company’s oral PK activator Pyrukynd (mitapivat) to…

Seeking Alpha | February 18, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5806 seconds.